The effect of infliximab on chemokines in patients with rheumatoid arthritis
Authors:
- 17 November 2006
- journal article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 26 (7) , 1088-1093
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by infiltration of lymphocytes, macrophages, and plasma cells into synovial membrane. The chemokines family promotes chemotactic activity in various leukocyte cell types. Chemokines thus play an essential role in the pathological formation of RA. The aim of the present study was to evaluate the influence of infliximab on serum levels of various chemokines. Twenty-four RA patients were involved in this study, which took place between March 2003 and February 2006. Infliximab was administered by intravenous infusion at a dosage of 3 mg/kg. All patients underwent general and physical examinations and routine blood and urinary analysis at the baseline, at 14 weeks, and at 30 weeks after the initial treatment. To determine whether serum and synovial fluid from RA also contained significant levels of chemokines compared with osteoarthritis patients (OA), GRO-α, MIP-1α, MIP-1β and regulated on activation normal T cell expressed and secreted (RANTES) levels of serum and synovial fluid were measured by ELISA in 20 RA patients and 20 OA patients. GRO-α, MIP-1β, and RANTES levels were significantly higher in RA compared with normal volunteers, while MIP-1α levels showed no significant differences. The mean GRO-α levels in serum from RA patients treated with infliximab decreased significantly after the initial treatment. The mean RANTES and MIP-1β levels did not change significantly after the treatment. Infliximab treatment significantly lowered the serum GRO-α levels of RA patients. GRO-α is one of the crucial cytokines affected by infliximab treatment. The blocking therapy of RANTES and MIP-1β combined with infliximab treatment may have an additional effect without competition in the TNFα cascade.Keywords
This publication has 29 references indexed in Scilit:
- Functional Distinction between CXC Chemokines, Interleukin-8 (IL-8), and Growth Related Oncogene (GRO)α in Neutrophil InfiltrationLaboratory Investigation, 2002
- In vitro migration of mononuclear cells towards synovial fluid and plasma from rheumatoid arthritis patients correlates to RANTES synovial fluid levels and to clinical pain parametersScandinavian Journal of Rheumatology, 2000
- Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1β production by synovial T cellsClinical and Experimental Immunology, 1995
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes.Journal of Experimental Medicine, 1992
- Neutrophil-Activating Proteins in PsoriasisJournal of Investigative Dermatology, 1992
- Properties of the Novel Proinflammatory Supergene "Intercrine" Cytokine FamilyAnnual Review of Immunology, 1991
- Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis.Journal of Clinical Investigation, 1991
- Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTESNature, 1990
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988